NEW YORK – OraSure Technologies announced Monday that its board of directors has authorized the repurchase of up to $40 million of the firm's common stock over the next 24 months.

纽约——OraSure Technologies 周一宣布，其董事会已授权在未来 24 个月内回购价值高达 4000 万美元的公司普通股。

The repurchase will be funded from cash on hand, the Bethlehem, Pennsylvania-based company said in a statement.

该公司在一份声明中表示，回购将由手头的现金资助。

Together with its wholly owned subsidiaries, DNA Genotek and

连同其全资子公司，DNA Genotek和

Sherlock Biosciences

夏洛克生物科学公司

, OraSure develops, manufactures, and distributes sample collection devices and rapid point-of-care and home-use diagnostic tests.

OraSure 开发、制造和分销样本收集设备以及快速即时检测和家用诊断测试。

OraSure may repurchase the shares through various methods, with the amount and timing determined by management at its discretion, the firm said, adding that the repurchase program may be modified, suspended, or discontinued at any time without prior notice.

该公司表示，OraSure 可以通过多种方法回购股份，回购的金额和时间由管理层自行决定，并补充说回购计划可能在任何时候被修改、暂停或终止，且无需事先通知。

Last month, OraSure reported a

上个月，OraSure 报告称

10 percent

百分之十

year-over-year increase in its 2024 fourth quarter core revenues, though its total revenues, including COVID-19 sales, declined 51 percent.

2024年第四季度核心收入同比增长，但包括新冠销售额在内的总收入下降了51%。

In early trading Monday on the Nasdaq, shares of OraSure were up approximately 21 percent to $4.21.

周一早盘交易中，OraSure的纳斯达克股价上涨约21％，至4.21美元。